Methods for Treatment with Bucindolol Based on Genetic Targeting
6 Assignments
0 Petitions
Accused Products
Abstract
The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor (AR).
-
Citations
123 Claims
-
1-94. -94. (canceled)
-
95. A method for evaluating bucindolol treatment for a patient comprising:
obtaining sequence information regarding a polymorphism in a β
1 adrenergic receptor (β
1AR) gene of the patient, wherein the information is predictive of bucindolol efficacy or adverse events in the patient.- View Dependent Claims (96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121)
-
122. A method for evaluating whether a heart failure patient will respond positively to bucindolol comprising:
-
a) obtaining information indicating the presence of a polymorphism at the coding position 1165 in the coding sequence of one or both β
1AR alleles of the patient or the presence of a polymorphism at the amino acid at position 389 of the β
1AR protein; andb) prescribing or administering bucindolol, if the patient has a β
1AR Arg389/Arg389 genotype;
or not prescribing or administering bucindolol if the patient does not have a β
1AR Arg389/Arg389 genotype.
-
-
123. A method for treating a patient comprising:
-
a) obtaining information indicating whether the patient has homozygous Arg389 genotype at β
1AR; andb) either prescribing bucindolol therapy for the patient wherein the patient'"'"'s genotype is homozygous Arg389 at the β
1AR protein or not prescribing bucindolol for the patient wherein the patient'"'"'s genotype is not homozygous Arg389 at the β
1AR protein.
-
Specification